NCCN Guidelines® Insights - Prostate Cancer, Version 5.2026

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease.

NCCN Guidelines® Insights - Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024 (JA copy)
These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
NCCN Guidelines® Insights - Merkel Cell Carcinoma, Version 1.2024 (JA copy)
These NCCN Guidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled “Clinical N0 Disease, Locally Advanced MCC.” This new algorithm page addresses locally advanced disease, and the panel clarifies the meaning behind the term “nonsurgical” by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.
NCCN Guidelines® Insights - Distress Management, Version 1.2026

The NCCN Guidelines for Distress Management discuss the identification and treatment of psychosocial problems in patients with cancer.

NCCN Guidelines® Insights - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026

Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)–containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic co

Behind the Guidelines: Insights into the Standard of Care in Oncology 2026 (NCCN Guidelines® Insights 2026)

In each issue of JNCCN, NCCN panel members shed light on the deliberation process behind the creation of the NCCN Guidelines, clarifying why and how these important decisions are made.

NCCN Guidelines® Insights - Small Cell Lung Cancer, Version 2.2026

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer provide recommendations for diagnostic workup, staging, and treatment.

NCCN Guidelines® Insights - Soft Tissue Sarcoma, Version 1.2025
The treatment landscape for soft tissue sarcomas (STS) is evolving constantly. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for STS specific to surgical management and systemic therapy recommendations for various subtypes.
NCCN Guidelines® Insights - Breast Cancer, Version 5.2025
The treatment landscape of invasive early-stage and metastatic breast cancer is evolving constantly. These NCCN Guidelines Insights focus on recent updates included in the most recent version (version 5.2025) of the NCCN Guidelines for Breast Cancer specific to workup, locoregional therapy, surveillance, and systemic neoadjuvant/adjuvant therapy recommendations for invasive, nonmetastatic breast cancer.

Pages

Subscribe to RSS - Monograph/Journal Supplement